USPTO serial 79346405
BARRIOLIDES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 3, 2023
- Examiner
- KAJUBI, ELIZABETH N
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BARRIOLIDES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Susan Fentress
Susan Fentress Veritay Group IP, PLLC3 North Dunlap st, VAN VLEET BUILDING Ssuite 332Memphis, TN 38103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; biological preparations for use in industry and science | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations to improve function of membranes in the body; pharmaceutical and veterinary preparations to improve function of membranes in the lung; pharmaceutical and veterinary preparations to enhance the epithelial barrier; pharmaceutical and veterinary preparations to enhance the airway epithelial barrier; pharmaceutical and veterinary preparations to inhibit inflammation; pharmaceutical and veterinary preparations for the treatment of a disease or condition that is caused by a defect in epithelial cells or tissue; pharmaceutical and veterinary preparations for the treatment of a disease or condition that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of a disease or condition of epithelial tissue in the respiratory tract; pharmaceutical and veterinary preparations for the treatment of epithelial dysfunction; pharmaceutical and veterinary preparations for the treatment of human airway epithelial cells; pharmaceutical and veterinary preparations for the treatment of chronic respiratory diseases; pharmaceutical and veterinary preparations for the treatment of viral airways diseases; pharmaceutical and veterinary preparations for the treatment of an airways disease; pharmaceutical and veterinary preparations for the treatment of asthma; pharmaceutical and veterinary preparations for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical and veterinary preparations for the treatment of cystic fibrosis; pharmaceutical and veterinary preparations for the treatment of non-cystic fibrosis bronchiectasis; pharmaceutical and veterinary preparations for the treatment of chronic rhinosinusitis; pharmaceutical and veterinary preparations for the treatment of diffuse panbronchiolitis (DPB); pharmaceutical and veterinary preparations for the treatment of chronic bronchitis; pharmaceutical and veterinary preparations for the treatment of bronchiolitis obliterans organizing pneumonia (BOOP); pharmaceutical and veterinary preparations for the treatment of infantile respiratory distress syndrome (IRDS); pharmaceutical and veterinary preparations for the treatment of bronchopulmonary dysplasia; pharmaceutical and veterinary preparations for the treatment of neuromuscular respiratory depression or failure; pharmaceutical and veterinary preparations for the treatment of pneumonia; pharmaceutical and veterinary preparations for the treatment of conditions caused by and associated with respiratory syncytial virus (RSV) and related viruses; pharmaceutical and veterinary preparations for the treatment of a disease or condition commonly associated with inflammation that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of systemic inflammatory distress syndrome (SIRS); pharmaceutical and veterinary preparations for the treatment of adult respiratory distress syndrome (ARDS); pharmaceutical and veterinary preparations for the treatment of inflammatory bowel disease; pharmaceutical and veterinary preparations for the treatment of ulcerative colitis; pharmaceutical and veterinary preparations for the treatment of Crohn's disease; sanitary preparations for medical purposes; dietary supplements for human beings and animals | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, scientific research in the field of pharmaceutical studies research, scientific research in new pharmaceutical design services, medical and pharmacological research services, drug discovery services, pharmaceutical drug development services, pharmaceutical research and development; industrial analysis and research services, namely, pharmaceutical analysis and pharmaceutical research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EpiEndo Pharmaceuticals ehf.
- Other trademarks owned by EpiEndo Pharmaceuticals ehf.
- Other trademarks owned by EpiEndo Pharmaceuticals ehf.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BARRIOLIDES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 30, 2024 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 8, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 8, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 3, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 3, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 3, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 28, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 18, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 15, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 14, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 14, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 14, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 14, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 14, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 14, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 22, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 22, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 31, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 30, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 24, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 20, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 9, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 4, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 3, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 28, 2022 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |